Jennifer D Ellis1, Jill A Rabinowitz2, Jonathan Wells3, Fangyu Liu4, Patrick H Finan1, Michael D Stein5, Denis G Antoine Ii1, Gregory J Hobelmann6, Andrew S Huhn7. 1. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Room 2717, Baltimore, MD 21224, USA. 2. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 3. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Division of Epidemiology, Department of Family Medicine and Population Health, Virginia Commonwealth University, Richmond, VA USA. 4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 5. Department of Health Law, Policy & Management, School of Public Health, Boston University, Boston, MA, USA. 6. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Room 2717, Baltimore, MD 21224, USA; Ashley Addiction Treatment, Havre de Grace, MD, USA. 7. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Room 2717, Baltimore, MD 21224, USA; Ashley Addiction Treatment, Havre de Grace, MD, USA. Electronic address: ahuhn1@jhu.edu.
Abstract
BACKGROUND: Understanding the course of anxiety and depressive symptoms in early opioid use disorder (OUD) treatment may inform efforts to promote positive early treatment response and reduce treatment attrition. METHODS: Persons in treatment for nonmedical opioid use were identified from 86 addiction treatment facilities. Growth mixture modeling was used to identify trajectories of anxiety and depression symptoms during the first month of treatment among individuals who screened positive for depression (N = 3016) and/or anxiety (N = 2779) at intake. RESULTS: A three-class solution best fit the data for anxiety symptoms and included the following trajectories: (1) persistent moderate-to-severe anxiety symptoms, (2) remitting severe anxiety symptoms, and (3) persistent minimal-to-mild anxiety symptoms. Similarly, a three-class solution best fit the data for depressive symptoms and included trajectories characterized by (1) persistent moderate-to-severe depressive symptoms, (2) persistent moderate depressive symptoms, and (3) mild/remitting depressive symptoms. Persistent moderate-to-severe anxiety and depressive symptoms were predicted by female gender and heavy past-month benzodiazepine co-use. LIMITATIONS: Fine grained-information about substance use was not collected. Results may not be generalizable to individuals receiving treatment outside of specialty addiction clinics. CONCLUSIONS: Analysis of anxiety and depression symptom trajectories in early treatment suggest that a subset of individuals entering treatment for opioid use experienced persistent and significant anxiety and depressive symptoms, whereas others experience a remission of symptoms. Interventions designed to target individuals at the greatest risk, such as women and individuals reporting opioid/benzodiazepine co-use, may help improve mental health symptoms in early OUD treatment.
BACKGROUND: Understanding the course of anxiety and depressive symptoms in early opioid use disorder (OUD) treatment may inform efforts to promote positive early treatment response and reduce treatment attrition. METHODS: Persons in treatment for nonmedical opioid use were identified from 86 addiction treatment facilities. Growth mixture modeling was used to identify trajectories of anxiety and depression symptoms during the first month of treatment among individuals who screened positive for depression (N = 3016) and/or anxiety (N = 2779) at intake. RESULTS: A three-class solution best fit the data for anxiety symptoms and included the following trajectories: (1) persistent moderate-to-severe anxiety symptoms, (2) remitting severe anxiety symptoms, and (3) persistent minimal-to-mild anxiety symptoms. Similarly, a three-class solution best fit the data for depressive symptoms and included trajectories characterized by (1) persistent moderate-to-severe depressive symptoms, (2) persistent moderate depressive symptoms, and (3) mild/remitting depressive symptoms. Persistent moderate-to-severe anxiety and depressive symptoms were predicted by female gender and heavy past-month benzodiazepine co-use. LIMITATIONS: Fine grained-information about substance use was not collected. Results may not be generalizable to individuals receiving treatment outside of specialty addiction clinics. CONCLUSIONS: Analysis of anxiety and depression symptom trajectories in early treatment suggest that a subset of individuals entering treatment for opioid use experienced persistent and significant anxiety and depressive symptoms, whereas others experience a remission of symptoms. Interventions designed to target individuals at the greatest risk, such as women and individuals reporting opioid/benzodiazepine co-use, may help improve mental health symptoms in early OUD treatment.
Authors: Bridget A Hearon; Amanda W Calkins; Daniella M Halperin; R Kathryn McHugh; Heather W Murray; Michael W Otto Journal: Am J Drug Alcohol Abuse Date: 2010-11-19 Impact factor: 3.829
Authors: Jaime Delgadillo; Scott Payne; Simon Gilbody; Christine Godfrey; Stuart Gore; Dawn Jessop; Veronica Dale Journal: Drug Alcohol Depend Date: 2012-04-04 Impact factor: 4.492
Authors: Kate H Bentley; Hitoshi Sakurai; Kelsey L Lowman; Lisa Rines-Toth; James McKowen; Paola Pedrelli; A Eden Evins; Amy M Yule Journal: J Affect Disord Date: 2021-01-07 Impact factor: 4.839
Authors: Albert J Burgess-Hull; Kirsten E Smith; Destiny Schriefer; Leigh V Panlilio; David H Epstein; Kenzie L Preston Journal: Drug Alcohol Depend Date: 2021-06-25 Impact factor: 4.852
Authors: Jennifer D Ellis; Chung Jung Mun; David H Epstein; Karran A Phillips; Patrick H Finan; Kenzie L Preston Journal: Neuropsychopharmacology Date: 2022-06-06 Impact factor: 8.294